European Union regulator has finally approved the coronavirus vaccine by Pfizer-BioNTech for Emergency usage in the European Union countries, European Medicines Agency EMA chief reported on Monday. The breakthrough statement from the European Medicines Agency (EMA) chief Emer Cooke reassured the people, the existing vaccine can work against the new variant of the novel coronavirus which is spreading fast in Uk, a claim nobody had made till now. 

In a press conference, Cooke said, "At this moment there is no evidence to suggest this vaccine will not work against the new variant". She further said, "EMA's scientific opinion paves the way for the first marketing authorisation of a #COVID19vaccine in the EU with the corresponding safeguards, controls and obligations". She extended thanks to the numerous scientists and health experts around the world for their continuous efforts said, "I am delighted to announce that the EMA scientific committee met today and recommended a conditional marketing authorisation in the EU for the vaccine developed by Pfizer and BioNTech". 

The approval was given after a careful scientific assessment based on the strength of the scientific evidence on the vaccine’s safety, quality and efficacy, and nothing else. The evidence convincingly shows that benefits are greater than the risks of this COVID-19 vaccine, she clarified. The main clinical trial for this vaccine, which enrolled over 43,000 people, is one of the largest we have ever evaluated for a vaccine, a historic trial of EMA, claimed Harald Enzmann, head of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). This decision will cover all 27 countries. 

WHO recommends strong action for containment in Europe

European markets tumble on tighter COVID-19 curbs

Angela Merkel urges Germans to see each other by video calls this Christmas